CN106692973A - 一种组合物及其用途、药物制剂 - Google Patents

一种组合物及其用途、药物制剂 Download PDF

Info

Publication number
CN106692973A
CN106692973A CN201610303976.5A CN201610303976A CN106692973A CN 106692973 A CN106692973 A CN 106692973A CN 201610303976 A CN201610303976 A CN 201610303976A CN 106692973 A CN106692973 A CN 106692973A
Authority
CN
China
Prior art keywords
acid
composition according
acceptable
preparation
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610303976.5A
Other languages
English (en)
Chinese (zh)
Inventor
刘利平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Hightide Biopharmaceutical Ltd
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Priority to CN202310452983.1A priority Critical patent/CN116492339A/zh
Priority to EP16901518.7A priority patent/EP3456328A4/en
Priority to KR1020187034961A priority patent/KR102892545B1/ko
Priority to IL300237A priority patent/IL300237A/en
Priority to JP2018559306A priority patent/JP2019518738A/ja
Priority to PCT/CN2016/105294 priority patent/WO2017193563A1/zh
Priority to CA3023648A priority patent/CA3023648C/en
Priority to AU2016406709A priority patent/AU2016406709C1/en
Publication of CN106692973A publication Critical patent/CN106692973A/zh
Priority to IL262929A priority patent/IL262929B2/en
Priority to JP2021180724A priority patent/JP7448511B2/ja
Priority to AU2023200123A priority patent/AU2023200123B2/en
Priority to JP2023189115A priority patent/JP7668859B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201610303976.5A 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂 Pending CN106692973A (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN202310452983.1A CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂
PCT/CN2016/105294 WO2017193563A1 (zh) 2015-11-13 2016-11-10 一种组合物及其用途、药物制剂
KR1020187034961A KR102892545B1 (ko) 2015-11-13 2016-11-10 조성물, 그 용도 및 약학적 제제
IL300237A IL300237A (en) 2015-11-13 2016-11-10 Preparations for treatment, methods for their preparation and their uses
JP2018559306A JP2019518738A (ja) 2015-11-13 2016-11-10 組成物、ならびにその適用および薬学的調製の方法
EP16901518.7A EP3456328A4 (en) 2016-05-10 2016-11-10 Composition, and application and pharmaceutical preparation thereof
CA3023648A CA3023648C (en) 2016-05-10 2016-11-10 Pharmaceutical composition of berberine with epa and dha
AU2016406709A AU2016406709C1 (en) 2016-05-10 2016-11-10 Composition, and application and pharmaceutical preparation thereof
IL262929A IL262929B2 (en) 2015-11-13 2018-11-11 Preparations for treatment, methods for their preparation and their uses
JP2021180724A JP7448511B2 (ja) 2015-11-13 2021-11-05 組成物、ならびにその適用および薬学的調製の方法
AU2023200123A AU2023200123B2 (en) 2016-05-10 2023-01-11 Composition, and application and pharmaceutical preparation thereof
JP2023189115A JP7668859B2 (ja) 2015-11-13 2023-11-06 組成物、ならびにその適用および薬学的調製の方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254739P 2015-11-13 2015-11-13
US62/254,739 2015-11-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310452983.1A Division CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂

Publications (1)

Publication Number Publication Date
CN106692973A true CN106692973A (zh) 2017-05-24

Family

ID=58939703

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310452983.1A Pending CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂
CN201610303976.5A Pending CN106692973A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310452983.1A Pending CN116492339A (zh) 2015-11-13 2016-05-10 一种组合物及其用途、药物制剂

Country Status (5)

Country Link
US (1) US11883539B2 (enExample)
JP (3) JP2019518738A (enExample)
KR (1) KR102892545B1 (enExample)
CN (2) CN116492339A (enExample)
IL (2) IL300237A (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
CN108159037A (zh) * 2017-12-29 2018-06-15 广东海洋大学 一种用于提高神经保护功能的不饱和脂肪酸组合物及其应用
WO2024245370A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101879162A (zh) * 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
CN102580087A (zh) * 2012-03-08 2012-07-18 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090289A1 (en) * 2006-02-09 2007-08-16 National Research Council Of Canada Combinations of botanical extracts for promoting cardiovascular health
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
JPWO2009028457A1 (ja) * 2007-08-29 2010-12-02 国立大学法人信州大学 非アルコール性脂肪肝炎治療薬
EP2405755A4 (en) * 2009-03-11 2012-11-28 Xintria Pharmaceutical Corp Inc METHOD AND COMPOSITIONS FOR TREATING METABOLISM AND CARDIOVASCULAR DISEASES
JP5640079B2 (ja) * 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
US9119826B2 (en) * 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
JP2014506891A (ja) * 2011-02-16 2014-03-20 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
EP3072510B1 (en) * 2012-03-30 2019-05-08 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
US8652518B2 (en) * 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
WO2014158256A1 (en) * 2013-03-13 2014-10-02 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
WO2014179325A1 (en) * 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
AU2015296098B2 (en) * 2014-07-29 2019-06-27 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
US9446100B2 (en) * 2015-02-13 2016-09-20 Eastern Vision Limited Dietary supplements and formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101879162A (zh) * 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
CN102580087A (zh) * 2012-03-08 2012-07-18 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108042522A (zh) * 2017-12-29 2018-05-18 广东海洋大学 一种用于提高抗炎症功能的不饱和脂肪酸组合物及其应用
CN108159037A (zh) * 2017-12-29 2018-06-15 广东海洋大学 一种用于提高神经保护功能的不饱和脂肪酸组合物及其应用
WO2024245370A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用途

Also Published As

Publication number Publication date
JP2022017496A (ja) 2022-01-25
US11883539B2 (en) 2024-01-30
IL262929B1 (en) 2023-03-01
KR102892545B1 (ko) 2025-12-09
JP7668859B2 (ja) 2025-04-25
IL262929A (en) 2018-12-31
CN116492339A (zh) 2023-07-28
IL300237A (en) 2023-03-01
JP2019518738A (ja) 2019-07-04
IL262929B2 (en) 2023-07-01
US20220296528A1 (en) 2022-09-22
JP2024014894A (ja) 2024-02-01
KR20230019269A (ko) 2023-02-08
JP7448511B2 (ja) 2024-03-12

Similar Documents

Publication Publication Date Title
JP7668859B2 (ja) 組成物、ならびにその適用および薬学的調製の方法
TWI841532B (zh) 以稠合雙環吡唑治療代謝疾病之方法
CN1258219A (zh) 苯并环庚并噻吩化合物
CN1915292A (zh) 益母草提取物作为拟胆碱药之乙酰胆碱酯酶抑制剂药物的用途
US11369573B2 (en) Pharmaceutical compositions of berberine with EPA and DHA, and methods thereof
WO2018232150A1 (en) Methods of treating rbp4 related diseases with triazolopyridines
US20240139165A1 (en) Methods and compositions for treatment of inflammatory bowel disease
AU2023200123B2 (en) Composition, and application and pharmaceutical preparation thereof
CN106822166B (zh) 一种防治糖尿病和高脂血症的药物及其在制药中的应用
CN1230178C (zh) 伴有前列腺肥大症的膀胱刺激症状治疗药
CN1923193A (zh) 一种香豆素类化合物在制备抗炎镇痛药物中的应用
CN107753527A (zh) 茯茶提取物及其在调节血脂和肝脏脂肪中的应用
CN101897714B (zh) 芍药苷的用途
CN106146488A (zh) 9‑位取代的双功能团小檗碱衍生物的制备方法及用途
CN105801663A (zh) 一种熊果酸小檗碱偶合物的制备方法及医药用途
CN106138048B (zh) 一种异喹啉生物碱的盐的降糖降脂保肝的用途
CN1290503C (zh) 复方樟柳碱口服液、制备方法及其用途
CN106265677B (zh) 一种防治溃疡性结肠炎的药物组合物及其应用
CN111166747A (zh) 药根碱在治疗和/或预防脂肪肝、减肥或糖尿病并发症药物中的应用
CN105213398B (zh) 一种治疗糖尿病的药物组合物
CN120241759A (zh) 防治代谢功能障碍相关性脂肪变性肝病的化合物及其应用
JP2001039883A (ja) 潰瘍性大腸炎の予防・治療用製剤ならびにその予防・治療方法
CN107970248A (zh) 异甘草酸在制备治疗高血压药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170524